{"d":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Subject(ID=70798L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/Subject(ID=70798L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.Subject"},"Meetings":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Meeting(ID=5201L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=5201L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.Meeting"},"Sessions":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=5201L,Language='DE')/Sessions"}},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=5201L,Language='DE')/Subjects"}},"ID":"5201","Language":"DE","MeetingNumber":11,"IdSession":5212,"SessionNumber":12,"SessionName":"Fr\u00fchjahrssession 2026","Council":1,"CouncilName":"Nationalrat","CouncilAbbreviation":"NR","Date":"\/Date(1773619200000)\/","Begin":"1430","Modified":"\/Date(1776247630025)\/","LegislativePeriodNumber":52,"PublicationStatus":"final","MeetingOrderText":"Elfte Sitzung","SortOrder":11,"Location":"N"},"SubjectsBusiness":{"results":[{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267204,IdSubject=70798L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267204,IdSubject=70798L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.SubjectBusiness"},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267204,IdSubject=70798L,Language='DE')/Subjects"}},"Businesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20267204,IdSubject=70798L,Language='DE')/Businesses"}},"IdSubject":"70798","BusinessNumber":20267204,"Language":"DE","BusinessShortNumber":"26.7204","Title":"modRNA Impfstoffe: Kein Vergleich mit herk\u00f6mmlichen Impfstoffen!","SortOrder":1,"PublishedNotes":null,"Modified":"\/Date(1773818217996)\/","TitleDE":"Fragestunde.\nFrage Gafner Andreas.\nmodRNA-Impfstoffe. Kein Vergleich\nmit herk\u00f6mmlichen Impfstoffen!","TitleFR":"Heure des questions.\nQuestion Gafner Andreas.\nVaccins \u00e0 ARN messager.\nAucune comparaison\navec les vaccins classiques !","TitleIT":null}]},"Transcripts":{"results":[{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Transcript(ID=371752L,Language='DE')","uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=371752L,Language='DE')","type":"itsystems.Pd.DataServices.DataModel.Transcript"},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=371752L,Language='DE')/Subjects"}},"MembersCouncil":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=371752L,Language='DE')/MembersCouncil"}},"Businesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=371752L,Language='DE')/Businesses"}},"ID":"371752","Language":"DE","IdSubject":"70798","VoteId":null,"PersonNumber":4238,"Type":1,"Text":"<pd_text><p>Die Zulassung der in der Frage angesprochenen Impfstoffe basiert auf vollst\u00e4ndigen nichtklinischen Pr\u00fcfprogrammen, die den internationalen Standards entsprechen und vor der Zulassung vollst\u00e4ndig bewertet wurden. Der Begutachtungsbericht ist auf der Website von Swissmedic publiziert. Zus\u00e4tzlich wurden Sicherheit und Wirksamkeit in umfangreichen klinischen Studien best\u00e4tigt, die ein konsistent positives Nutzen-Risiko-Profil zeigten. Die wissenschaftlichen Anforderungen f\u00fcr eine regul\u00e4re Zulassung sind damit erf\u00fcllt. </p>\n<p>Jede Impfung ist freiwillig. Fachpersonen m\u00fcssen ein Impfgespr\u00e4ch f\u00fchren und \u00fcber Nutzen und Risiken informieren. Das BAG stellt daf\u00fcr ein Informationsblatt zur Covid-19-Impfung in der Schwangerschaft bereit, welches das Gespr\u00e4ch erg\u00e4nzt, aber nicht ersetzt. Die Impfempfehlung f\u00fcr Schwangere beruht auf einer Nutzen-Risiko-Abw\u00e4gung durch das BAG und die Eidgen\u00f6ssische Kommission f\u00fcr Impffragen, welche die wissenschaftliche Evidenz laufend pr\u00fcfen.</p>\n</pd_text>","MeetingCouncilAbbreviation":"N","MeetingDate":"20260316","MeetingVerbalixOid":4144,"IdSession":"5212","SpeakerFirstName":"Elisabeth","SpeakerLastName":"Baume-Schneider","SpeakerFullName":"Baume-Schneider Elisabeth","SpeakerFunction":"BR-F","CouncilId":99,"CouncilName":"Bundesrat","CantonId":26,"CantonName":"Jura","CantonAbbreviation":"JU","ParlGroupName":null,"ParlGroupAbbreviation":null,"SortOrder":1,"Start":"\/Date(1773673145690)\/","End":"\/Date(1773673221289)\/","Function":"BR-F","DisplaySpeaker":true,"LanguageOfText":"DE","Modified":"\/Date(1790250099379)\/","StartTimeWithTimezone":"\/Date(1773673145690+0060)\/","EndTimeWithTimezone":"\/Date(1773673221290+0060)\/","VoteBusinessNumber":null,"VoteBusinessShortNumber":null,"VoteBusinessTitle":null}]},"ID":"70798","Language":"DE","IdMeeting":"5201","VerbalixOid":796872,"SortOrder":18,"Modified":"\/Date(1790250099374)\/"}}